We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
PharmaFrontiers announced that their research of their Phase I/II clinical trials of Tovaxin, a novel T cell therapeutic vaccine for multiple sclerosis, has been accepted for presentation at the 21st Congress of the European Committee/10th Annual Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis, to be held this fall in Thessaloniki, Greece.
CytRx reported that the FDA has provided a written explanation of the reasons for the clinical hold placed on the company's Phase II trial for its oral drug candidate arimoclomol for the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease).
ZymoGenetics has presented the aggregate results of four Phase II clinical studies of recombinant human Thrombin (rhThrombin) at the International Society on Thrombosis and Hemostasis annual meeting in Sydney, Australia.
OncoGenex Technologies has announced that the first patient has been treated in a Phase II clinical trial of OGX-011, in combination with gemcitabine and cisplatin, (GEM and CIS) in chemotherapy naive patients with advanced non-small cell lung cancer (NSCLC).
Cytomedix has completed the treatment phase of a clinical trial involving 72 patients at 14 sites designed to test the safety and effectiveness of its AutoloGel system for diabetic foot ulcers.
Polydex Pharmaceuticals provided an update of ongoing human clinical trials of Ushercell, a cellulose sulfate gel envisioned for use as a contraceptive and for the prevention of HIV and other sexually transmitted diseases.
Array BioPharma has an investigational new drug (IND) application now in effect with the FDA for ARRY-334543, allowing Array to proceed with human clinical studies in cancer patients.
BioCryst Pharmaceuticals announced that it has initiated a Phase Ib trial of BCX-4208, the company's second generation, transition-state analog inhibitor of purine nucleoside phosphorylase.